ChemotherapyPhase 3 trialInvestigational
Doxorubicin
How it works
Damages the DNA of cancer cells, preventing them from reproducing. It also triggers the immune system to attack cancer cells.
Cancer types
Breast Cancer— All patients
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Understanding Doxorubicin Resistance in Breast Cancer Cells | Breast Cancer | lab-study | — | Source → |
| Combining Peptide and Doxorubicin May Help Treat Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Myoglobin's Role in Breast Cancer Treatment Response | Breast Cancer | lab-study | — | Source → |
| Plant Compounds Enhance Chemotherapy in Colorectal Cancer Cells | Colorectal Cancer | lab-study | Combined treatments with doxorubicin significantly reduced cell viability to approximately 10% in Caco2 cells. | Source → |
| Exosomes May Contribute to Doxorubicin Resistance in Breast Cancer | Breast Cancer | lab-study | — | Source → |
| FTY720 Makes Cancer Cells More Sensitive to Doxorubicin | Leukemia | lab-study | — | Source → |
| Researchers Identify Metabolic Patterns Linked to Heart Damage in Breast Cancer Patients | Breast Cancer | lab-study | — | Source → |
| Chemotherapy Resistance in Breast Cancer Linked to Blood Vessel Changes | Breast Cancer | animal-study | — | Source → |
| Researchers Study How Tumors Resist Chemotherapy | Breast Cancer | lab-study | — | Source → |
| Researchers Create Resistant Leukemia Cells to Study Drug Resistance | Leukemia | lab-study | — | Source → |
| Understanding Doxorubicin's Heart Damage in Cancer Treatment | Breast Cancer | review | — | Source → |
| DNA Damage Repair Pathways and Doxorubicin-Resistant Breast Cancer | Breast Cancer | review | — | Source → |
| Researchers Identify How Lung Cancer Cells Resist Chemotherapy | Lung Cancer | lab-study | — | Source → |
| New Biomarker for Heart Damage from Cancer Treatment | Breast Cancer | phase-2 | — | Source → |
| New Nanocarriers for Delivering Cancer Medicine | Breast Cancer | lab-study | The nanocarriers exhibited pronounced pH-dependent doxorubicin release and enhanced cytotoxicity toward MCF-7 cells (IC₅₀ = 0.8 ± 0.1 μM) | Source → |
| Evaluating Dapagliflozin to Prevent Heart Damage from Doxorubicin | Breast Cancer | phase-2 | — | Source → |
| Testing Treatments for Advanced Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Microneedle Patch Improves Doxorubicin Delivery for Breast Cancer | Breast Cancer | animal-study | Tumor inhibition rate was 90.61% in a 4T1 tumor-bearing mouse model. | Source → |
| Doxorubicin Resistance Found in Leukemia Cells Grown in Lab | Leukemia | lab-study | Only 0.26±0.21% of the resistant cells entered late apoptosis after 24h doxorubicin exposure. | Source → |
| Understanding Resistance to Doxorubicin in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Nanoparticle Delivery System Shows Promise for Lung Cancer Treatment | Lung Cancer | lab-study | The IC50 value was 1.36 μM, compared to 1.9 μM for free DOX. | Source → |
| Pegylated Liposomal Doxorubicin and Immunotherapy in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Detecting Cancer Drug Concentration in Cells | Breast Cancer | lab-study | — | Source → |
| Overcoming Doxorubicin Resistance in Ovarian Cancer Cells | Ovarian Cancer | lab-study | Substantial resensitization of A2780ADR cells to Doxo was achieved by verapamil (Ver). | Source → |
| Doxorubicin Resistance in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| TBX20 linked to doxorubicin resistance in breast cancer cells | Breast Cancer | lab-study | — | Source → |
| Combining Peptide and Chemotherapy May Help Treat Breast Cancer | Breast Cancer | lab-study | Nisin demonstrated cytotoxic effect against breast cancer MCF-7 and MDA-MB-231 cells with IC50 values of 5-8 µM. | Source → |
| Combining Doxorubicin and Zm-093 May Enhance Apoptosis in Breast Cancer Cells | Breast Cancer | lab-study | The combined treatment resulted in a 57% reduction in Bcl-2 expression compared to the control group. | Source → |
| Combining drugs may help fight aggressive breast cancer | Breast Cancer | lab-study | Treatment with SB431542 and doxorubicin used in combination significantly reduced cell viability (CDI 0.54-0.63) | Source → |
| New Delivery System for Colorectal Cancer Treatment | Colorectal Cancer | lab-study | The tumor suppression rate reached 42.55 ± 0.18%. | Source → |
| Long non-coding RNA STMN1P2 linked to breast cancer resistance to doxorubicin | Breast Cancer | lab-study | — | Source → |
| New Compound Shows Promise in Treating Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Dichloroacetate Enhances Chemotherapy Effectiveness in Some Breast Cancer Cells | Breast Cancer | lab-study | The cell line MCF7 exhibited the highest rate of inhibition, followed by MDA-MB-231 and T47D. | Source → |
| Doxorubicin's kidney damage linked to SIRT1/HSF1 pathway | Ovarian Cancer | animal-study | — | Source → |
| Ovarian Cancer and Heart Damage: New Research and Treatment Strategies | Ovarian Cancer | review | — | Source → |
| Combining Cold Plasma and Doxorubicin May Help Fight Melanoma | Melanoma | meta-analysis | The pooled analysis found that the CAP and DOX combination had a significant effect on cell viability (ES = 6.75, 95% CI 1.65 to 11.85) and cytotoxicity (ES = 11.71, 95% CI 3.69 to 19.73). | Source → |
| Viscosity Affects Colon Cancer Cells' Resistance to Doxorubicin | Colorectal Cancer | lab-study | — | Source → |
| New Tool Helps Target Cancer Treatment with Light | Ovarian Cancer | lab-study | — | Source → |
| Pegylated Liposomal Doxorubicin Shows Promise in Ovarian Cancer Treatment | Ovarian Cancer | phase-2 | The median progression-free survival was 6.8 months (95% CI, 4.4-9.3 months), and the median overall survival was 19.1 months (95% CI, 15.0-23.3 months). | Source → |
| Understanding Chemotherapy Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| New Hydrogel System Tested for Treating Melanoma | Melanoma | lab-study | — | Source → |
| Understanding Doxorubicin's Effectiveness in Breast Cancer Treatment | Breast Cancer | lab-study | — | Source → |
| Nanoparticles Deliver Cancer Drugs More Effectively | Breast Cancer | lab-study | BBR/CS-DOX demonstrated stronger pro-apoptotic and anti-metastatic effect in vitro and in vivo, respectively | Source → |
| Doxorubicin Resistance Linked to Gene Expression Changes | Colorectal Cancer | lab-study | — | Source → |
| Researchers Investigate Doxorubicin Resistance in Leukemia Cells | Leukemia | lab-study | — | Source → |
| Propofol May Enhance Effectiveness of Ovarian Cancer Treatments | Ovarian Cancer | lab-study | — | Source → |
| Cancer Gene Linked to Doxorubicin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | The tumor growth inhibition rate rose in the si-CASC11 group in comparison with that in the si-NC group (P < 0.05). | Source → |
| Cancer Cells May Develop Resistance to Doxorubicin with Help from Surrounding Tissue Cells | Ovarian Cancer | lab-study | — | Source → |
| Cadmium-based Complex Loaded with Doxorubicin Shows Promise Against Leukemia | Leukemia | lab-study | — | Source → |
| Targeted Cancer Treatment Shows Promise for Colorectal Cancer | Colorectal Cancer | lab-study | DOX-P exhibited superior antitumor activity against colorectal cancer than that of DOX. | Source → |
| STK32C and Doxorubicin Resistance in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Targeted Cancer Therapy Using Smart Nanosystem | Breast Cancer | lab-study | — | Source → |
| Trabectedin's Role in Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
| Ovarian Cancer Cells Show Resistance to Platinum-Based Chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| New Compound Enhances Effectiveness of Cancer Treatment in Lab Experiments | Breast Cancer | lab-study | — | Source → |
| Cardiac MRI Helps Predict Heart Damage in Cancer Survivors | Leukemia | lab-study | — | Source → |
| Drug Interactions in Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| New Nanoparticles Show Promise in Treating Breast Cancer | Breast Cancer | lab-study | The cell viability declined to 13.98% in 24 hours at a concentration of 60 μg mL. | Source → |
| Combining Doxorubicin and Oleanolic Acid May Improve Pancreatic Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| Combining Trimetazidine and Doxorubicin May Improve Cancer Treatment | Breast Cancer | animal-study | The DOX/TMZ combination exhibited a synergistic effect at both DOX/TMZ 1:10 and 1:5 ratios. | Source → |
| New Nanosystem for Treating Melanoma Cancer | Melanoma | lab-study | — | Source → |
| Insulin's Effect on Breast Cancer Cells' Resistance to Doxorubicin | Breast Cancer | lab-study | — | Source → |
| New Options for Ovarian Cancer Treatment | Ovarian Cancer | meta-analysis | The risk of death was significantly decreased with carboplatin + pegylated liposomal doxorubicin + bevacizumab compared to platinum-based doublet CT (hazard ratio [HR] = 0.59, 95%CI 0.35, 1). | Source → |
| GATA3 linked to doxorubicin resistance in breast cancer | Breast Cancer | lab-study | — | Source → |
| Doxorubicin Chemotherapy's Long-Term Effect on Children's Hearts | Leukemia | observational | — | Source → |
| New Cancer Treatment Combination Shows Promise in Ovarian Cancer | Ovarian Cancer | preclinical | The objective response rate was 27.7% (95% CI 17.3% to 40.2%), including one complete (1.5%) and 17 partial responses (26.2%), with median duration of response of 7.6 (95% CI 3.3 to 10.2) months and median progression-free survival of 5.0 (95% CI 3.2 to 6.0) months. | Source → |
| Combining Hesperidin and Doxorubicin May Help Treat Aggressive Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Caffeic Acid Phenethyl Ester May Help Overcome Chemotherapy Resistance in Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Naringin May Help Reduce Liver Damage from Doxorubicin | Leukemia | lab-study | — | Source → |
| New Nanocarriers Deliver Cancer Drugs More Effectively | Breast Cancer | lab-study | Nio-Cis-Dox-AL showed appropriate encapsulation efficiencies of 65.54 ± 1.25% and 80.65 ± 1.80% for Cis and Dox, respectively. | Source → |
| Dexrazoxane Protects Heart Function in Childhood Cancer Survivors | Leukemia | phase-3 | Dexrazoxane was associated with a reduced risk of having lower left ventricular function (odds ratio, 0.24 [95% CI, 0.07 to 0.81]). | Source → |
| Targeted Cancer Treatment Shows Promise in Lab Experiments | Breast Cancer | lab-study | — | Source → |
| Hypertension and Heart Failure in Breast Cancer Patients | Breast Cancer | observational | The RAS inhibitor group had a lower risk for primary outcome (adjusted HR = 0.78, 95% CI = 0.65-0.94) and death (adjusted HR = 0.81, 95% CI = 0.66-0.99) compared to the non-HT group. | Source → |
| Lubeluzole May Help Cancer Treatment Work Better | Ovarian Cancer | lab-study | — | Source → |
| Combining Cancer Treatments May Improve Effectiveness in Breast Cancer Cells | Breast Cancer | lab-study | The triple-combination synergistically inhibited cell growth, achieving a combination index of 0.672 and 0.157 in MDA-MB-231 and MCF-7 cells, respectively. | Source → |
| Optimizing Chemotherapy Schedules for Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Combining Epigenetic and Chemotherapy Treatments for Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Combination Therapy Tested in Ovarian Cancer Patients | Ovarian Cancer | phase-2 | The overall objective response rate was 8.7%. | Source → |
| Vitamin E and Doxorubicin Combination in Breast Cancer Cells | Breast Cancer | lab-study | The antiproliferative effect of doxorubicin increased significantly in combination with vitamin E (P=0.000). | Source → |
| Circular RNA May Contribute to Breast Cancer Progression and Treatment Resistance | Breast Cancer | lab-study | CircATXN7 silencing suppressed breast cancer development and doxorubicin resistance. | Source → |
| New Approach to Target Prostate Cancer with Fewer Side Effects | Prostate Cancer | lab-study | — | Source → |
| Combining Two Drugs in Nanoparticles to Fight Resistant Breast Cancer | Breast Cancer | lab-study | The (DOX + CUR)-FA-NPs displayed the highest cell apoptosis and cellular uptake in MCF-7/ADR cells. | Source → |
| Camel Urine May Enhance Effectiveness of Cancer Treatment | Breast Cancer | lab-study | — | Source → |
| Anthracyclines in Patients with Heart Failure and Leukemia | Leukemia | observational | — | Source → |
| Loperamide Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin | Breast Cancer | lab-study | Adding Loperamide to Doxorubicin reduced its IC50 by twofolds compared with Doxorubicin alone. | Source → |
| Combining Cisplatinum and Doxorubicin May Help Treat Rare Breast Cancer | Breast Cancer | animal-study | Only the combination treatment regressed the tumor. | Source → |
| Targeted Nanoparticles Help Deliver Cancer Medicine | Breast Cancer | lab-study | — | Source → |
| MicroRNAs and Doxorubicin Resistance in Breast Cancer | Breast Cancer | review | — | Source → |
| Researchers Develop New Bone Cement to Deliver Cancer-Fighting Medicine | Lung Cancer | animal-study | — | Source → |
| Enhancing Doxorubicin's Effect on Breast Cancer with New Nanoparticles | Breast Cancer | lab-study | — | Source → |
| Combining Two Drugs to Treat Advanced Ovarian Cancer | Ovarian Cancer | phase-1 | The overall response rate was 27.8%. | Source → |
| Combining Apigenin and Doxorubicin May Help Treat Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Rare Case of Breast Cancer Patient Survives Twice with Chemotherapy | Breast Cancer | observational | — | Source → |
| Cancer Protein Silencing May Help Overcome Doxorubicin Resistance | Breast Cancer | lab-study | — | Source → |
| New Approach to Treating Triple Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| LRP1B Protein May Help Predict Response to Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| Targeting Prion Protein to Overcome Chemotherapy Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.